AU2018282225B2 - T cells with reduced surface fucosylation and methods of making and using the same - Google Patents

T cells with reduced surface fucosylation and methods of making and using the same Download PDF

Info

Publication number
AU2018282225B2
AU2018282225B2 AU2018282225A AU2018282225A AU2018282225B2 AU 2018282225 B2 AU2018282225 B2 AU 2018282225B2 AU 2018282225 A AU2018282225 A AU 2018282225A AU 2018282225 A AU2018282225 A AU 2018282225A AU 2018282225 B2 AU2018282225 B2 AU 2018282225B2
Authority
AU
Australia
Prior art keywords
cells
animal
reduced surface
surface fucosylation
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018282225A
Other languages
English (en)
Other versions
AU2018282225A1 (en
Inventor
Jessica FIELD
Shyra Gardai
Ryan Heiser
Nicole OKELEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of AU2018282225A1 publication Critical patent/AU2018282225A1/en
Assigned to SEAGEN INC. reassignment SEAGEN INC. Amend patent request/document other than specification (104) Assignors: SEATTLE GENETICS, INC.
Application granted granted Critical
Publication of AU2018282225B2 publication Critical patent/AU2018282225B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AU2018282225A 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same Ceased AU2018282225B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516536P 2017-06-07 2017-06-07
US62/516,536 2017-06-07
PCT/US2018/036067 WO2018226701A1 (en) 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same

Publications (2)

Publication Number Publication Date
AU2018282225A1 AU2018282225A1 (en) 2019-12-12
AU2018282225B2 true AU2018282225B2 (en) 2024-06-13

Family

ID=62751563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018282225A Ceased AU2018282225B2 (en) 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same

Country Status (17)

Country Link
US (2) US11891644B2 (enExample)
EP (1) EP3634427A1 (enExample)
JP (1) JP7245177B2 (enExample)
KR (1) KR102687149B1 (enExample)
CN (1) CN110740734A (enExample)
AU (1) AU2018282225B2 (enExample)
BR (1) BR112019025775A2 (enExample)
CA (1) CA3065524A1 (enExample)
EA (1) EA201992875A1 (enExample)
IL (1) IL271012B2 (enExample)
MA (1) MA50865A (enExample)
MX (1) MX2019014584A (enExample)
SG (1) SG11201911617SA (enExample)
TW (1) TW201903144A (enExample)
UA (1) UA128783C2 (enExample)
WO (1) WO2018226701A1 (enExample)
ZA (1) ZA201907623B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021034774A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2012019165A2 (en) * 2010-08-05 2012-02-09 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
PT3102609T (pt) 2014-02-04 2024-10-23 Us Health Métodos de produção de células t autólogas úteis para o tratamento de malignidades das células b e de outros cancros e respetivas composições
US11400115B2 (en) 2014-04-23 2022-08-02 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
MX2017000646A (es) 2014-07-15 2017-04-27 Juno Therapeutics Inc Celulas geneticamente modificadas para terapia celular adoptiva.
MX2017003062A (es) 2014-09-09 2017-12-14 Unum Therapeutics Receptores quimericos y usos de los mismos en terapia inmune.
EP3227323B1 (en) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
IL292504B2 (en) 2015-10-20 2024-01-01 Kite Pharma Inc Methods of preparing T cells for T cell therapy
SG11201804263PA (en) * 2015-12-04 2018-06-28 Seattle Genetics Inc Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Also Published As

Publication number Publication date
CN110740734A (zh) 2020-01-31
JP7245177B2 (ja) 2023-03-23
CA3065524A1 (en) 2018-12-13
US20240117400A1 (en) 2024-04-11
EP3634427A1 (en) 2020-04-15
IL271012B2 (en) 2023-12-01
MX2019014584A (es) 2020-02-07
JP2020523014A (ja) 2020-08-06
US11891644B2 (en) 2024-02-06
EA201992875A1 (ru) 2020-03-25
WO2018226701A1 (en) 2018-12-13
KR20200015580A (ko) 2020-02-12
TW201903144A (zh) 2019-01-16
MA50865A (fr) 2020-04-15
ZA201907623B (en) 2024-04-24
US20200149082A1 (en) 2020-05-14
KR102687149B1 (ko) 2024-07-24
SG11201911617SA (en) 2020-01-30
IL271012A (en) 2020-01-30
UA128783C2 (uk) 2024-10-23
BR112019025775A2 (pt) 2020-06-23
AU2018282225A1 (en) 2019-12-12
IL271012B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
Sadeghzadeh et al. Dendritic cell therapy in cancer treatment; the state-of-the-art
US20230092130A1 (en) Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20240117400A1 (en) T cells with reduced surface fucosylation and methods of making and using the same
CN112426526B (zh) 一种nk细胞的制备方法及其在治疗癌症中的应用
EP3154567B1 (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
JP5792622B2 (ja) ナチュラルキラー細胞の製造方法
CN114786687A (zh) 用于过继细胞疗法的Cbl抑制剂和组合物
Yang et al. Adoptive cellular therapy (ACT) for cancer treatment
TW202208617A (zh) 用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途
TW202327631A (zh) 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者
US9944898B2 (en) Method of generating tumor-specific T cells
TW202239415A (zh) 腫瘤浸潤性淋巴球療法與ｃｔｌａ－４及ｐｄ－１抑制劑組合之治療
JP2021535082A (ja) 免疫エフェクター細胞を使用して腫瘍を治療する方法
WO2011131944A1 (en) Methods for obtaining dendritic cells
Deng et al. Prospects and limitations of NK cell adoptive therapy in clinical applications
Duncan et al. Dendritic cell vaccines in acute leukaemia
CN112755051B (zh) 一种nk细胞的制备及治疗癌症中的应用
TW202300014A (zh) 腫瘤儲存及細胞培養組成物
HK40018054A (en) T cells with reduced surface fucosylation and methods of making and using the same
JP7390740B2 (ja) 腫瘍の治療及び／又は予防のための組成物
Zeng et al. NKT cell: Success and promises in transplantation and immunotherapy
Li et al. Successes and challenges of NKT cell immunotherapy: Breaking tolerance to cancer resistance
WO2025068608A1 (en) Method for the stimulation of t cells with il-4 and tnf alpha
CN117715647A (zh) 用nk细胞和cd38靶向抗体治疗癌症
CN117545490A (zh) 用nk细胞和her2靶向抗体治疗癌症

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SEAGEN INC.

Free format text: FORMER NAME(S): SEATTLE GENETICS, INC.

FGA Letters patent sealed or granted (standard patent)